Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry.


Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 20 9 2018
medline: 9 7 2020
entrez: 20 9 2018
Statut: ppublish

Résumé

Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative disease. Over time, symptoms accumulate leading to increased disability of patients. The objective of this article is to analyze the prevalence of symptoms and symptomatic treatment patterns in a nationwide MS registry. Data sets from 35,755 patients were analyzed. More than two-thirds of patients were women with a mean age of 46.1 (±12.8) years. Median Expanded Disability Status Score (EDSS) was 3.0. The most frequently reported symptoms were fatigue, spasticity, and voiding disorders. In patients with short disease duration, fatigue was reported most frequently. Symptomatic treatment was most common for spasticity and depression, whereas fatigue was treated only in a third of affected patients. Almost a fifth of patients with EDSS ⩽ 3.5 and neuropsychological symptoms had retired from work. Whereas treatment for spasticity and depression is common in our cohort, sexual dysfunction, dysphagia, cognitive dysfunction, and fatigue are treated to a far lesser extent. The need for psychological support, physical, and occupational therapy has to be recognized as neuropsychological symptoms have a great impact on retirement at an early stage. Overall symptomatic treatment rates for the most common symptoms have increased over the last years (

Sections du résumé

BACKGROUND
Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative disease. Over time, symptoms accumulate leading to increased disability of patients.
OBJECTIVE
The objective of this article is to analyze the prevalence of symptoms and symptomatic treatment patterns in a nationwide MS registry.
METHODS
Data sets from 35,755 patients were analyzed.
RESULTS
More than two-thirds of patients were women with a mean age of 46.1 (±12.8) years. Median Expanded Disability Status Score (EDSS) was 3.0. The most frequently reported symptoms were fatigue, spasticity, and voiding disorders. In patients with short disease duration, fatigue was reported most frequently. Symptomatic treatment was most common for spasticity and depression, whereas fatigue was treated only in a third of affected patients. Almost a fifth of patients with EDSS ⩽ 3.5 and neuropsychological symptoms had retired from work.
CONCLUSION
Whereas treatment for spasticity and depression is common in our cohort, sexual dysfunction, dysphagia, cognitive dysfunction, and fatigue are treated to a far lesser extent. The need for psychological support, physical, and occupational therapy has to be recognized as neuropsychological symptoms have a great impact on retirement at an early stage. Overall symptomatic treatment rates for the most common symptoms have increased over the last years (

Identifiants

pubmed: 30230952
doi: 10.1177/1352458518799580
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1641-1652

Auteurs

Paulus Stefan Rommer (PS)

Department of Neurology, Neuroimmunological Section, University of Rostock, Rostock, Germany/Department of Neurology, Medical University of Vienna, Vienna, Austria.

Kerstin Eichstädt (K)

MS Forschungs- und Projektentwicklungs-gGmbH, Hannover, Germany.

David Ellenberger (D)

Department of Medical Statistics, University Medical Centre Göttingen, Göttingen, Germany.

Peter Flachenecker (P)

Neurological Rehabilitation Center Quellenhof, Bad Wildbad, Germany.

Tim Friede (T)

Department of Medical Statistics, University Medical Centre Göttingen, Göttingen, Germany.

Judith Haas (J)

MS-Center, Jewish Hospital Berlin, Berlin, Germany.

Christoph Kleinschnitz (C)

Department of Neurology, University Hospital Essen, Essen, Germany.

Dieter Pöhlau (D)

Department of Neurology, German Red Cross-Kamillus-Clinic, Asbach, Germany.

Otto Rienhoff (O)

Department of Medical Informatics, University Medical Center Göttingen, Göttingen, Germany.

Alexander Stahmann (A)

MS Forschungs- und Projektentwicklungs-gGmbH, Hannover, Germany.

Uwe Klaus Zettl (UK)

Department of Neurology, Neuroimmunological Section, University of Rostock, Rostock, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH